FDA Expands Spravato Label to Allow Standalone Treatment for Resistant Depression

The U.S. Food and Drug Administration expanded the prescribing options for Spravato in January 2025, allowing the esketamine nasal spray to be used alone for adults with treatment-resistant depression. Previously framed around use with an oral antidepressant, that indication now permits either approach. Reuters reported the announcement on January 21. Read the contemporaneous Reuters report.

What the FDA actually approved

The agency’s supplemental approval letter describes an expansion to include Spravato monotherapy for treatment-resistant depression, along with corresponding revisions to the prescribing information and medication guide. The decision concerns a specific product and indication, not a blanket authorization for ketamine-based psychiatric services. The FDA approval letter sets out the change.

The revised label states that Spravato is indicated for treatment-resistant depression in adults as monotherapy or with an oral antidepressant. That wording is the key regulatory development: concurrent oral antidepressant treatment is no longer required under this particular indication. Read the updated indications.

Why the distinction matters

For patients and prescribers, the expansion creates another way to structure treatment. It does not establish that every patient should discontinue an oral medication, and it does not provide a universal switching protocol. The question of whether to retain, replace, or discontinue another prescription remains separate from the fact that monotherapy is permitted.

It also changes how clinics should describe eligibility and treatment choices. A description that says Spravato must always be combined with an oral antidepressant is incomplete for the revised treatment-resistant depression indication. A description that says oral antidepressants are never required is also incomplete because the label contains a second indication with different conditions.

The separate acute-symptom indication remains different

For depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, the label continues to specify use with an oral antidepressant. It also states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. The label distinguishes the two indications.

That limitation is important in reporting the expansion. A regulatory decision about standalone treatment-resistant depression therapy should not be recast as a new suicide-prevention approval or as evidence that clinical crisis care is no longer necessary.

Supervised treatment requirements stay in place

Spravato remains available through a restricted Risk Evaluation and Mitigation Strategy, or REMS. Patients require monitoring for at least two hours after administration because of risks including sedation, dissociation, and respiratory depression. The boxed warning also addresses abuse and misuse. Review the boxed warning and REMS requirements.

In other words, monotherapy describes the medication combination, not the treatment setting. The expanded indication does not turn Spravato into a routine take-home prescription or remove the observation period.

Publication adds detail to the evidence base

A randomized clinical trial of esketamine monotherapy was published online in JAMA Psychiatry in July 2025. The study compared esketamine nasal spray with placebo in adults with treatment-resistant depression, providing peer-reviewed detail about the standalone approach. Read the trial record and abstract.

The trial and the regulatory action answer related but distinct questions. The trial evaluates efficacy and safety under its study conditions. The FDA label defines the approved use and the precautions required in prescribing. Neither should be replaced by a generalized claim that all ketamine treatments now have the same evidence.

What patients should clarify

• Which Spravato indication applies to their diagnosis?
• Whether an oral antidepressant remains part of the proposed plan?
• How benefits and adverse effects will be tracked?
• What supervised visits and transportation arrangements require?
• Who manages any changes to existing medication?

The central news is a broader approved option for adults with treatment-resistant depression. The boundaries are equally important: a specific esketamine product, a defined adult indication, continued monitoring, and no instruction for patients to change prescriptions on their own.

Sources

• FDA: Supplemental approval letter
• FDA: January 2025 Spravato label
• Reuters: January 21, 2025 coverage
• JAMA Psychiatry: Monotherapy trial